In addition, FDA has approved combinations of anti-VEGF/VEGFR with anti-PD-1/PD-L1 agents in hepatocellular carcinoma and renal cell carcinoma. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.